ArticleBiochemical and biophysical research communications2007
The green tea component EGCG inhibits RNA polymerase III transcription.
Article in Biochemical and biophysical research communications, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Pooled it
- The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy.Frontiers in immunology · 2024Review
- Preventing Persistence of HPV Infection with Natural Molecules.Pathogens (Basel, Switzerland) · 2023Review
- Epigallocatechin-3-gallate Can Prevent Type 2 Human PapillomavirusInternational journal of molecular sciences · 2021Article
- Suppressive Effects of EGCG on Cervical Cancer.Molecules (Basel, Switzerland) · 2018Review
- Gender Specific Differences in RNA Polymerase III Transcription.Journal of carcinogenesis & mutagenesis · 2016Article
- Induction of proto-oncogene BRF2 in breast cancer cells by the dietary soybean isoflavone daidzein.BMC cancer · 2015Article
- TFIIB-related factor 2 is associated with poor prognosis of nonsmall cell lung cancer patients through promoting tumor epithelial-mesenchymal transition.BioMed research international · 2014Article
- Article
- Overexpression of TFIIB-related factor 2 is significantly correlated with tumor angiogenesis and poor survival in patients with esophageal squamous cell cancer.Medical oncology (Northwood, London, England) · 2013Article
- Going Green: The Role of the Green Tea Component EGCG in Chemoprevention.Journal of carcinogenesis & mutagenesis · 2013Article
- INMAP, a novel truncated version of POLR3B, represses AP-1 and p53 transcriptional activity.Molecular and cellular biochemistry · 2013Article
- RNA polymerase III transcription in cancer: the BRF2 connection.Molecular cancer · 2011Review
- Inhibition of U6 snRNA Transcription by PTEN.OnLine journal of biological sciences · 2010Article
- Differential expression of the TFIIIB subunits Brf1 and Brf2 in cancer cells.BMC molecular biology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
RNA polymerase III (RNA pol III) transcribes many small structural RNA molecules involved in RNA processing and translation, and thus regulates the growth rate of a cell. Accurate initiation by RNA pol III requires the initiation factor TFIIIB. TFIIIB has been demonstrated to be regulated by tumor suppressors, including ARF, p53, RB, and the RB-related pocket proteins, and is a target of the oncogene c-myc and the mitogen-activated protein kinase ERK. EGCG has been demonstrated to inhibit the growth of a variety of cancer cells, induce apoptosis and regulate the expression of p53, myc, and ERK. Thus, we hypothesized that EGCG may regulate RNA pol III transcription in cells. Here, we report that EGCG (1) inhibits RNA pol III transcription from gene internal and gene external promoters (2) EGCG inhibits protein expression of the TFIIIB subunits Brf1 and Brf2, and (3) EGCG inhibits Brf2 promoter activity in cervical carcinoma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.